Clinical Trial Update: CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating CGT9486 (PLX9486) as a single agent and in combination with PLX3397 (pexidartinib) or sunitinib in participants with advance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumors

Drugs mentioned

• CGT9486 (PLX9486)
• PLX3397 (Pexidartinib) (Pexidartinib)
• Sunitinib (sunitinib)

Snippet

Sponsor: Cogent Biosciences, Inc. | Conditions: Gastrointestinal Stromal Tumors | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-02-14